Here are the 10-K annual reports from OmniAb, Inc. Warrant (OABIW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow OABIW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OABIW filings page.
OmniAb, Inc. provides a licensing-based antibody discovery platform used by pharmaceutical, biotech and academic partners to develop next‑generation therapeutics. Its transgenic animal technologies, AI‑driven screening and ion channel expertise are designed to generate fully human, high‑quality antibody candidates across many disease areas.
OmniAb’s business model centers on platform access fees, research services, milestones and downstream royalties on partner products. As of December 31, 2025, the company reported 107 active partners and 407 active programs, including 27 clinical programs, two antibodies under regulatory review and three approved, partner‑commercialized products.